Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
Stanley T. Crooke, M.D., Ph.D. and Barry E. Greene to Step Down
LA JOLLA, Calif., Nov. 7, 2012
LA JOLLA, Calif., Nov. 7, 2012 /PRNewswire/ --Regulus Therapeutics Inc.
(NASDAQ: RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, announced today the
appointment of Douglas E. Williams, Ph.D. to its Board of
Directors.Concurrently, Stanley T. Crooke, M.D., Ph.D., Chairman of the Board
and CEO of Isis Pharmaceuticals, Inc., and Barry E. Greene, President and
Chief Operating Officer of Alnylam Pharmaceuticals, Inc., have each stepped
down from the Board of Directors and their respective Board committees.
"I want to thank Stan and Barry for their leadership and for their many
contributions during the past formative years of the company.During their
service on the Board, Regulus has transitioned from an up-start to an emerging
publicly traded biopharmaceutical company," said John Maraganore, Ph.D.,
Chairman of Regulus' Board of Directors."I would also like to welcome Doug to
the Board and look forward to his contributions as we continue to build a
"I also want to thank Stan and Barry for their wonderful service and many
contributions to the Board," said Kleanthis G. Xanthopoulos, Ph.D., President
and CEO of Regulus."I'd also like to welcome Doug to the Board.He is a
recognized biotech leader with a proven track record of more than twenty years
in drug development, research and operations. Given our recently completed
public offering and focus on clinical development, Doug's addition to our
Board comes at the right time as we advance multiple microRNA programs toward
"This is an exciting time to join the outstanding team at Regulus," said Dr.
Williams. "Regulus is in a strong position to capture the transformative
potential of microRNA therapeutics and create powerful, first-in-class
Dr. Williams serves as Executive Vice President of Research and Development at
Biogen Idec. He joined Biogen Idec from ZymoGenetics Inc., where he was most
recently CEO and member of the Board of Directors. Previously, he held
leadership positions within the biotechnology industry, including Chief
Scientific Officer and Executive Vice President of Research and Development at
Seattle Genetics Inc., and Senior Vice President and Washington Site Leader at
Amgen Inc. Dr. Williams also served in a series of scientific and senior
leadership positions over a decade at Immunex Corp., including Executive Vice
President and Chief Technology Officer, Senior Vice President of Discovery
Research and Vice President of Research and Development.
Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company
leading the discovery and development of innovative medicines targeting
microRNAs. Regulus is leveraging a mature therapeutic platform based on
technology that has been developed over 20 years. Regulus works with a broad
network of academic collaborators and leverages the oligonucleotide drug
discovery and development expertise of its founding companies, Alnylam
Pharmaceuticals (NASDAQ: ALNY) and Isis Pharmaceuticals (NASDAQ: ISIS).
Regulus is advancing microRNA therapeutics toward clinical development in
several areas, including oncology, fibrosis, hepatitis C and metabolic
diseases. Regulus has formed strategic alliances with AstraZeneca,
GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.
For more information, please visit http://www.regulusrx.com.
Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with Regulus' expectations regarding future therapeutic and
commercial potential of Regulus' business plans, technologies and intellectual
property related to microRNA therapeutics being discovered and developed by
Regulus. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks
and uncertainties, which include, without limitation, risks associated with
the process of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of building a
business around such drugs.These and other risks concerning Regulus' programs
are described in additional detail in Regulus' SEC filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Regulus undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.
SOURCE Regulus Therapeutics Inc.
Contact: Amy Conrad, Director, Investor Relations and Corporate
Communications, Regulus Therapeutics Inc., +1-858-202-6300,
email@example.com, or Media, David Schull, Russo Partners LLC,
Press spacebar to pause and continue. Press esc to stop.